Skip to main content
. 2022 Feb 8;12:812598. doi: 10.3389/fonc.2022.812598

Figure 6.

Figure 6

Co-treatment of Cqn enhances the antitumor efficacy of Utt-B against HCC, in NOD-SCID mice bearing HepG2 xenografts. (A, B) Tumor images and Graphical representation of final tumor volume of different groups. (C, D) Western blot analysis demonstrating enhanced cleavage of caspase 9 motherband and PARP in the group co-treated with Cqn and Utt-B, compared to control and individual treatments. (E) Increase in TUNEL-positive cells in the group co-treated with Cqn and Utt-B, confirming enhancement in apoptosis (F, G) Immunohistochemical analysis of nuclear proliferation markers PCNA, ki67 and the autophagy marker LC3-II and Apoptotic marker Cleaved PARP. ** level of significance 2, **** level of significance 4. Data represent three independent sets of experiments. The error bars represent the Standard Deviation. Statistical significance was analysed by Student’s t test. ****P ≤ 0.0001; **P ≤ 0.01. Symbol asterisk (*) represents statistical significance between control and treatment groups (B).